Rituximab cuts autoantibodies to insulin in study

08/18/2011 | HealthDay News

Rituximab treatment worked better than a placebo in suppressing autoantibodies to insulin in patients with new-onset type 1 diabetes, a study in Diabetes found. About 40% of rituximab-treated patients had no IAAs after a year, while no patient on the placebo had the same result, researchers said.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park